Bruker (BKD) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BKD Analyst Ratings

Moderate Buy

4 Buy

5 Hold

1 Sell

Based on 10 analysts giving stock ratings to

Bruker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BKD Stock 12 Month Forecast

Average Price Target

€49.47

▼(-6.95% Downside)

Based on 10 Wall Street analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is €49.47 with a high forecast of €61.11 and a low forecast of €34.92. The average price target represents a -6.95% change from the last price of €53.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"€26","35":"€35","44":"€44","53":"€53","62":"€62"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61.1149287,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€61.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.47398989999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€49.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.9228164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,35,44,53,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.94,54.49191759230769,55.04383518461538,55.59575277692308,56.14767036923077,56.69958796153846,57.25150555384615,57.80342314615385,58.355340738461535,58.90725833076923,59.45917592307692,60.011093515384616,60.563011107692304,{"y":61.1149287,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.94,53.59646076153846,53.25292152307692,52.90938228461538,52.565843046153844,52.222303807692306,51.87876456923077,51.53522533076922,51.191686092307684,50.848146853846146,50.50460761538461,50.16106837692307,49.81752913846153,{"y":49.47398989999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.94,52.477139723076924,51.01427944615384,49.55141916923077,48.08855889230769,46.625698615384614,45.16283833846154,43.69997806153846,42.237117784615386,40.77425750769231,39.31139723076923,37.84853695384616,36.38567667692308,{"y":34.9228164,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.966,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.334,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.264,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.106,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.362,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.218,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.742,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.702,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.982,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.483,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.501,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€61.11

Average Price Target€49.47

Lowest Price Target€34.92

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evie Koslosky

Goldman Sachs

€30.56→€34.92

Sell

-34.32%

Downside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: MannKind (NASDAQ: MNKD), Bruker (NASDAQ: BRKR) and BrightSpring Health Services, Inc. (NASDAQ: BTSG)

Daniel Brennan

TD Cowen

€39.29→€52.38

Hold

-1.48%

Downside

Reiterated

07/15/26

Bruker price target raised to $60 from $45 at TD CowenBruker price target raised to $60 from $45 at TD Cowen

Patrick B Donnelly

Citi

€38.42→€52.38

Hold

-1.48%

Downside

Reiterated

07/08/26

Bruker price target raised to $60 from $44 at CitiBruker price target raised to $60 from $44 at Citi

Subbu Nambi

Guggenheim

€43.65→€61.11

Buy

14.94%

Upside

Reiterated

06/29/26

Bruker price target raised to $70 from $50 at GuggenheimBruker price target raised to $70 from $50 at Guggenheim

Luke Sergott

Barclays

€46.27→€52.38

Buy

-1.48%

Downside

Assigned

06/24/26

Barclays Sticks to Their Buy Rating for Bruker (BRKR)

Casey Woodring

J.P. Morgan

€39.29→€56.75

Buy

6.73%

Upside

Reiterated

06/08/26

Bruker price target raised to $65 from $45 at JPMorganBruker price target raised to $65 from $45 at JPMorgan

Michael Ryskin

Bank of America Securities

€42.78→€56.75

Buy

6.73%

Upside

Reiterated

06/02/26

Bruker (BRKR) Receives a Buy from Bank of America Securities

Michael Polark

Wolfe Research

―

Hold

―

Downgraded

06/01/26

Bruker assumed at Peer Perform from Outperform at Wolfe ResearchBruker assumed at Peer Perform from Outperform at Wolfe Research

Daniel Arias

Stifel Nicolaus

€34.92→€39.29

Hold

-26.11%

Downside

Assigned

05/08/26

Bruker price target raised to $45 from $40 at StifelBruker price target raised to $45 from $40 at Stifel

Dan Leonard

RBC Capital

€34.92→€39.29

Hold

-26.11%

Downside

Assigned

05/07/26

Bruker price target raised to $45 from $40 at UBSBruker price target raised to $45 from $40 at UBS

Tycho Peterson

Jefferies

€48.02→€43.65

Buy

-17.90%

Downside

Reiterated

02/12/26

Bruker price target lowered to $50 from $55 at JefferiesBruker price target lowered to $50 from $55 at Jefferies

Brandon Couillard

Wells Fargo

€41.91→€48.02

Buy

-9.69%

Downside

Reiterated

12/15/25

Bruker price target raised to $55 from $48 at Wells FargoBruker price target raised to $55 from $48 at Wells Fargo

Natalya Davies

Rothschild & Co Redburn

€52.38

Buy

-1.48%

Downside

Reiterated

11/20/25

Bruker initiated with a Buy at Rothschild & Co RedburnBruker initiated with a Buy at Rothschild & Co Redburn

Jack Meehan

Nephron

―

Hold

―

Upgraded

11/03/25

Bruker upgraded to Hold from Sell at Nephron ResearchBruker upgraded to Hold from Sell at Nephron Research

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

09/07/25

Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic Initiatives

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evie Koslosky

Goldman Sachs

€30.56→€34.92

Sell

-34.32%

Downside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: MannKind (NASDAQ: MNKD), Bruker (NASDAQ: BRKR) and BrightSpring Health Services, Inc. (NASDAQ: BTSG)

Daniel Brennan

TD Cowen

€39.29→€52.38

Hold

-1.48%

Downside

Reiterated

07/15/26

Bruker price target raised to $60 from $45 at TD CowenBruker price target raised to $60 from $45 at TD Cowen

Patrick B Donnelly

Citi

€38.42→€52.38

Hold

-1.48%

Downside

Reiterated

07/08/26

Bruker price target raised to $60 from $44 at CitiBruker price target raised to $60 from $44 at Citi

Subbu Nambi

Guggenheim

€43.65→€61.11

Buy

14.94%

Upside

Reiterated

06/29/26

Bruker price target raised to $70 from $50 at GuggenheimBruker price target raised to $70 from $50 at Guggenheim

Luke Sergott

Barclays

€46.27→€52.38

Buy

-1.48%

Downside

Assigned

06/24/26

Barclays Sticks to Their Buy Rating for Bruker (BRKR)

Casey Woodring

J.P. Morgan

€39.29→€56.75

Buy

6.73%

Upside

Reiterated

06/08/26

Bruker price target raised to $65 from $45 at JPMorganBruker price target raised to $65 from $45 at JPMorgan

Michael Ryskin

Bank of America Securities

€42.78→€56.75

Buy

6.73%

Upside

Reiterated

06/02/26

Bruker (BRKR) Receives a Buy from Bank of America Securities

Michael Polark

Wolfe Research

―

Hold

―

Downgraded

06/01/26

Bruker assumed at Peer Perform from Outperform at Wolfe ResearchBruker assumed at Peer Perform from Outperform at Wolfe Research

Daniel Arias

Stifel Nicolaus

€34.92→€39.29

Hold

-26.11%

Downside

Assigned

05/08/26

Bruker price target raised to $45 from $40 at StifelBruker price target raised to $45 from $40 at Stifel

Dan Leonard

RBC Capital

€34.92→€39.29

Hold

-26.11%

Downside

Assigned

05/07/26

Bruker price target raised to $45 from $40 at UBSBruker price target raised to $45 from $40 at UBS

Tycho Peterson

Jefferies

€48.02→€43.65

Buy

-17.90%

Downside

Reiterated

02/12/26

Bruker price target lowered to $50 from $55 at JefferiesBruker price target lowered to $50 from $55 at Jefferies

Brandon Couillard

Wells Fargo

€41.91→€48.02

Buy

-9.69%

Downside

Reiterated

12/15/25

Bruker price target raised to $55 from $48 at Wells FargoBruker price target raised to $55 from $48 at Wells Fargo

Natalya Davies

Rothschild & Co Redburn

€52.38

Buy

-1.48%

Downside

Reiterated

11/20/25

Bruker initiated with a Buy at Rothschild & Co RedburnBruker initiated with a Buy at Rothschild & Co Redburn

Jack Meehan

Nephron

―

Hold

―

Upgraded

11/03/25

Bruker upgraded to Hold from Sell at Nephron ResearchBruker upgraded to Hold from Sell at Nephron Research

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

09/07/25

Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic Initiatives

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bruker

3 Months

Luke SergottBarclays

Success Rate

8/15 ratings generated profit

Average Return

+2.81%

Copying Luke Sergott's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +2.81% per trade.

1 Year

Luke SergottBarclays

Success Rate

11/15 ratings generated profit

Average Return

+27.09%

Copying Luke Sergott's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +27.09% per trade.

2 Years

Luke SergottBarclays

Success Rate

14/15 ratings generated profit

Average Return

+42.75%

Copying Luke Sergott's trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +42.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BKD Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BKD has received 6 Buy Ratings, 7 Hold Ratings, and 2 Sell Ratings. BKD average Analyst price target in the past 3 months is 49.47.

Each month's total comprises the sum of three months' worth of ratings.

BKD Financial Forecast

BKD Earnings Forecast

Next quarter’s earnings estimate for BKD is €0.33 with a range of €0.32 to €0.35. The previous quarter’s EPS was €0.27. BKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year BKD has Performed in-line its overall industry.

BKD Sales Forecast

Next quarter’s sales forecast for BKD is €739.88M with a range of €730.61M to €751.17M. The previous quarter’s sales results were €713.73M. BKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year BKD has Performed in-line its overall industry.

BKD Stock Forecast FAQ

What is DE:BKD’s average 12-month price target, according to analysts?

Based on analyst ratings, Bruker Corp’s 12-month average price target is 49.47.

What is DE:BKD’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:BKD, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bruker Corp a Buy, Sell or Hold?

Bruker Corp has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 5 hold ratings and 1 sell ratings.

What is Bruker Corp’s share price target?

The average share price target for Bruker Corp is 49.47. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €61.11 ,and the lowest forecast is €34.92. The average share price target represents -6.95% Decrease from the current price of €53.17.

What do analysts say about Bruker Corp?

Bruker Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Bruker Corp?

To buy shares of DE:BKD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bruker (BKD) Stock Forecast & Price Target

BKD Analyst Ratings

BKD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bruker

BKD Analyst Recommendation Trends

BKD Financial Forecast

BKD Earnings Forecast

BKD Sales Forecast

BKD Stock Forecast FAQ

Detailed List of Analyst Forecasts